Siemens Fonds Invest GmbH trimmed its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 87.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,135 shares of the medical research company's stock after selling 22,764 shares during the period. Siemens Fonds Invest GmbH's holdings in Amgen were worth $817,000 as of its most recent SEC filing.
A number of other large investors have also recently bought and sold shares of AMGN. Centricity Wealth Management LLC bought a new stake in Amgen in the fourth quarter valued at $25,000. Pinney & Scofield Inc. acquired a new position in Amgen in the fourth quarter worth $26,000. Ritter Daniher Financial Advisory LLC DE boosted its stake in Amgen by 66.2% in the fourth quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock worth $33,000 after purchasing an additional 51 shares in the last quarter. Synergy Investment Management LLC acquired a new position in Amgen in the fourth quarter worth $34,000. Finally, Atala Financial Inc acquired a new position in Amgen in the fourth quarter worth $34,000. 76.50% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
AMGN has been the topic of a number of recent analyst reports. Piper Sandler reduced their price objective on Amgen from $329.00 to $328.00 and set an "overweight" rating on the stock in a research note on Friday, May 16th. Wells Fargo & Company reaffirmed an "equal weight" rating on shares of Amgen in a research note on Wednesday, February 5th. Erste Group Bank lowered Amgen from a "strong-buy" rating to a "hold" rating in a research note on Thursday, May 8th. Johnson Rice set a $294.00 price target on Amgen in a research note on Wednesday, March 5th. Finally, Citigroup reaffirmed a "neutral" rating on shares of Amgen in a research note on Wednesday, February 5th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $309.22.
View Our Latest Analysis on AMGN
Amgen Trading Up 0.1%
Shares of Amgen stock traded up $0.29 during trading hours on Monday, hitting $288.47. The company's stock had a trading volume of 2,393,911 shares, compared to its average volume of 2,805,108. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85. The stock has a 50 day moving average of $283.12 and a 200 day moving average of $285.27. The company has a market capitalization of $155.11 billion, a PE ratio of 38.21, a price-to-earnings-growth ratio of 2.63 and a beta of 0.51. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95.
Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.18 by $0.72. Amgen had a return on equity of 176.32% and a net margin of 12.24%. The company had revenue of $8.15 billion during the quarter, compared to the consensus estimate of $8.05 billion. During the same period in the prior year, the company earned $3.96 earnings per share. The company's revenue for the quarter was up 9.4% compared to the same quarter last year. Analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.
Amgen Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be given a $2.38 dividend. The ex-dividend date is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.30%. Amgen's payout ratio is 86.86%.
About Amgen
(
Free Report)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Read More
Before you consider Amgen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.
While Amgen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
